Connect Biopharma Holdings Limited (CNTB)
Develops an experimental antibody drug to treat severe asthma and COPD attacks
$2.08-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+4.0%
The outlook
CNTB is trading near $2.08, well below both its 50- and 200-day moving averages, positioning it in the lower part of its 52-week range. Analyst consensus is strongly bullish with an average price target about 243% above the current level. The overall picture reflects significant analyst optimism paired with a stock that's recently underperformed.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 8 analysts
Price trendBelow its 50- & 200-day averages
52-week range33% of the way from its 52-week low to high
Price targetAvg target +243% vs current price
Analyst price target
~12-month · 8 analysts$7.13average target+242.5% vs now
Now $2.08
Low $4.00High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$131.0M
52-wk high
$3.82
52-wk low
$1.23
50-day avg
$2.25
200-day avg
$2.40
Trailing P/E
—